S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
OTCMKTS:ARGSQ

Argos Therapeutics (ARGSQ) Stock Price, News & Analysis

$0.05
0.00 (0.00%)
(As of 10/10/2019)
Today's Range
$0.05
$0.05
50-Day Range
$0.05
$0.05
52-Week Range
$0.02
$0.25
Volume
N/A
Average Volume
13,394 shs
Market Capitalization
$571,698.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ARGSQ stock logo

About Argos Therapeutics Stock (OTCMKTS:ARGSQ)

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

ARGSQ Stock Price History

ARGSQ Stock News Headlines

ARGSQ Historical Data
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Outrage as Argos sells G-strings for children
Argos
See More Headlines
Receive ARGSQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Argos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2017
Today
4/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ARGSQ
Fax
N/A
Employees
21
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.90 million
Book Value
($1.63) per share

Miscellaneous

Free Float
N/A
Market Cap
$571,698.00
Optionable
Not Optionable
Beta
2.47
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Charles A. Nicolette (Age 57)
    Consultant
  • Mr. Jeffrey D. Abbey (Age 57)
    Consultant & Director
  • Dr. Richard D. Katz (Age 55)
    Consultant
  • Ms. Lori R. Harrelson CPA (Age 50)
    CPA, VP of Fin.
  • Mr. William N. Wofford
    Sec.

ARGSQ Stock Analysis - Frequently Asked Questions

How have ARGSQ shares performed in 2024?

Argos Therapeutics' stock was trading at $0.0540 on January 1st, 2024. Since then, ARGSQ stock has increased by 0.0% and is now trading at $0.0540.
View the best growth stocks for 2024 here
.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc (OTCMKTS:ARGSQ) issued its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) EPS for the quarter, topping analysts' consensus estimates of ($4.50) by $0.30. The biopharmaceutical company earned $0.07 million during the quarter, compared to analysts' expectations of $0.10 million.

When did Argos Therapeutics' stock split?

Argos Therapeutics shares reverse split on Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Argos Therapeutics?

Shares of ARGSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ARGSQ) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners